Gene transfer technology in therapy: Current applications and future goals

Stem Cells

Volumn 17, Issue 4, 1999, Pages 191-202

  Romano, Gaetano ^a   Pacilio, Carmen ^b   Giordano, Antonio ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adeno associated virus; Adenovirus; Cationic liposomes; Clinical trials; Gene delivery systems in vivo or in vitro; Gene therapy; Retroviruses

Indexed keywords

VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; NEUROLOGIC DISEASE;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032798121     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.170191     Document Type: Article

References (136)

1. Wolff JA, Lederberg J. An early history of gene transfer and therapy. Hum Gene Ther 1994;5:469-480.
2. Blaese RM, Culver KW, Anderson WF. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990;1:331-337.
3. Anderson WF. End-of-the-year potpourri-1995. Hum Gene Ther 1995;6:1505-1506.
4. Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-578.
5. Osanto S, Brouwenstyn N, Vaessen N et al. Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum Gene Ther 1993;4:323-330.
6. Arienti F, Sule-Suso J, Belli F et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogenic melanoma cells. Hum Gene Ther 1996;7:1955-1963.
7. Nabel GJ, Gordon D, Bishop DK et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-15393.
8. Klatzman D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther 1996;7:255-267.
9. Stopeck AT, Hersh EM, Akporiaye ET et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341-349.
10. Mahvi DM, Sondel PM, Yang NS et al. Phase I/IB study of immunization with autologous tumor cells transduced with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 1997;8:875-891.
11. Deshane J, Siegal GP, Wang M et al. Transductional efficiency and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer therapy. Gynecol Oncol 1997;64:378-385.
12. Kun LE, Gajjar A, Muhlbauer M et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA 317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 1995;6:1231-1255.
13. Nguyen DM, Spitz FR, Yen N et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systematic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996;112:1372-1376.
14. Haynes BF. HIV vaccines: where we are and where we are going. Lancet 1996;348:933-937.
15. Weber J. Distinguishing between response to HIV vaccine and response to HIV. Lancet 1996;350:230-231.
16. Romano G, Massi D, Giordano A. The standpoint of AIDS research and therapy programs. Anticancer Res, (in press).
17. Boyer J, Ugen K, Wang B et al. Protection of chimpanzees from high dose heterologous challenge by DNA vaccination. Nat Med 1997;3:526-532.
18. Rowland-Jones S, McMichael A. Role of CTL in HIV pathogenesis. Curr Opin Immunol 1995;7:448.
19. Wain-Hobson S. In: Morse SSB, ed. The Evolutionary Biology of Retroviruses. New York: Raven, 1994:185-209.
20. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
21. Ho DD, Neumann AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
22. Coumoyer D, Caskey CT. Gene therapy of the immune system. Annu Rev Immunol 1993;11:297-329.
23. Gilboa E. Retroviral gene transfer. Applications to human gene therapy. Prog Clin Biol Res 1990;352:301-311.
24. Kohn DB, Anderson WF, Blaese MB. Gene therapy for genetic diseases. Cancer Invest 1989;7:179-192.
25. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990;1:5-14.
26. Temin HM. Retrovirus vectors for gene transfer: efficient integration into and expression of exogenous DNA in vertebrate cell genomes. In: Kucherlapati R, ed. Gene Transfer. New York: Plenum Press, 1986:144-187.
27. Blacklow NR, Hoggan MD, Kapikian AZ et al. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968;88:368-378.
28. Berns KI, Pinkerton TC, Thomas GF et al. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 1975;68:556-560.
29. Cheung AK, Hoggan MD, Hauswirth WW et al. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 1980;3:739-748.
30. Podsakoff G, Wong KK Jr, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994;68:5656-5666.
31. Kotin RM, Berns KI. Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology 1989;170:460-467.
32. Kotin RM, Siniscalco M, Samulski RJ et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87:2211-2215.
33. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992;11:5071-5078.
34. Kotin RM, Menninger JC, Ward DC et al. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991;10:831-834.
35. Samulski RJ, Zhu X, Xiao X et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-3950.
36. Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994;91:8915-8919.
37. Rowe WP, Huebner RJ, Gilmore LK et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953;84:570-573.
38. Stewart PL, Burnett RM, Cyrlaff M et al. Image reconstruction reveals the complex molecular organization of adenovirus. Cell 1991;67:145-154.
39. Stewart PL, Fuller SD, Burnett RM. Difference imaging of adenovirus: bridging the resolution gap between x-ray crystallography and electron microscopy. EMBO J 1993;12:2589-2599.
40. Ballay A, Levrero M, Buendia MA et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J 1985;4:3861-3865.
41. Karlsson S, Van Doren K, Schweiger SG et al. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J 1985;5:2377-2385.
42. Yamada M, Lewis JA, Grodzicker T. Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector. Proc Natl Acad Sci USA 1985;82:3597-3571.
43. Stratford-Perricaudet LD, Levrero M, Chasse JF et al. Evaluation of the transfer and expression in mice of an enzyme encoding gene using a human adenovirus vector. Hum Gene Ther 1990;1:241-256.
44. Lemarchand P, Jaffe HA, Danel C et al. Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA 1992;89:6482-6486.
45. Rosenfeld MA, Yoshimura K, Trapnell BC et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143-155.
46. Glorioso JC, De Luca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 1995;49:675-710.
47. Thierry AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioates and liposomal encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 1992;20:5691-5698.
48. Bennet CF, Chiang MY, Chan H et al. Cationic lipids enhance cellular uptake and activity of phosphothioate antisense oligonucleotides. Mol Pharmacol 1992;41:1023-1033.
49. Ropert C, Malvy C, Couvreur P. Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. Pharm Res 1993;10:1427-1433.
50. Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 1993;190:952-960.
51. Ryser HP, Shen WC. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 1978;75:3867-3870.
52. 4-poly(L-lisine) conjugates in intact cells. Biochemistry 1986;25:3730-3736.
53. Naldini L, Blomer U, Gallat P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
54. Naldini L, Blomer U, Gage FH et al. Efficient gene transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996;93:11382-11388.
55. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996;93:11395-11399.
56. Srinivasakumar N, Chazal N, Prasad CH-MS et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997;71:5841-5848.
57. Zufferey R, Nagy D, Mandel RJ et al. Multiple attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-875.
58. Kim VN, Mitrophanous K, Kingsman SM et al. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998;72:811-816.
59. Mocarski ES, Kemble GW, Lyle JM et al. A deletion mutant in the human cytomegalovirus gene encoding IE14910 is replication defective due to a failure in autoregulation. Proc Natl Acad Sci USA 1996;93:11321-11326.
60. Robertson ES, Ooka T, Kieff ED. Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc Natl Acad Sci USA 1996;93:11334-11340.
61. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-11348.
62. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-11353.
63. Palese P, Zheng H, Engelhardt OG et al. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA 1996;93:11354-11358.
64. Frolov I, Hoffman TA, Pragai BM et al. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA 1996;93:11371-11377.
65. Duboise SM, Guo J, Desrosiers RC et al. Use of virion DNA as a cloning vector for the construction of mutant and recombinant herpesviruses. Proc Natl Acad Sci USA 1996;93:11389-11394.
66. Feng M, Jackson WH, Goldman CK et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotech 1997;15:866-870.
67. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection, Mol Cell Biol 1990;10:4239-4242.
68. Shinnick TM, Lerner RA, Sutcliffe JG. Nucleotide sequence of Moloney murine leukemia virus. Nature 1981;293:543-548.
69. Takeuchi Y, Cosset FL, Lackmann PJ et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994;68:8001-8007.
70. Burns JC, Friedman T, Driever W et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian cells. Proc Natl Acad Sci USA 1993;90:8033-8037.
71. Yee J-K, Miyanohara A, LaPorte P et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994;91:9564-9568.
72. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 1992;66:5110-5113.
73. Pear WS, Nolan GP, Scott ML et al. Production of helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-8396.
74. Finer MH, Dull TJ, Qin L et al. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994;83:43-50.
75. Soneoka Y, Cannon PM, Ramsdale EE et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995;23:628-633.
76. Romano G, Guan M, Long WK et al. Differential effects on HIV-1 gene regulation by EBV in T lymphocytic and promonocytic cells transduced to express recombinant human CR2 (CD21). Virology 1997;237:23-32.
77. Hawley RG, Lieu FHL, Fong AZC et al. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994;1:136-138.
78. Yu SF, von Ruden T, Kantoff PW et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986;83:3194-3198.
79. Hofmann A, Nolan GP, Blau HM, Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 1996;93:5185-5190.
80. Young JAT, Bates P, Willen K et al. Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 1990;250:1421-1423.
81. Matano T, Odawara T, Iwamoto A et al. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 1995;76:3165-3169.
82. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993;21:1081-1085.
83. Chu T-HT, Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 1995;69:2659-2663.
84. Chu TH, Dornburg R. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 1997;71:720-725.
85. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995;92:9747-9751.
86. Valsesia-Wittman S, Drynda A, Deleage G et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994;68:4609-4619.
87. Kasahara K, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994;266:1373-1376.
88. Valsesia-Wittman S, Morling FJ, Nilson BHK et al. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol 1996;70:2059-2064.
89. Wickham TJ, Roelvink PW, Brough DE et al. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotech 1996;14:1570-1573.
90. Douglas JT, Rogers BE, Rosenfeld ME et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotech 1996;14:1574-1578.
91. Ohno K, Sawai K, Iijima Y et al. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotech 1997;15:763-767.
92. Mebatsion T, Finke S, Weiland F et al. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997;90:841-847.
93. Schnell MJ, Johnson JE, Buonocore L et al. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997;90:849-857.
94. Berson JF, Long D, Dorantz BJ et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996;70:6288-6295.
95. Feng Y, Broder CC, Kennedy PE et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
96. Weinberg JB, Matthews TJ, Cullen BR et al. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 1991;174:1477-1482.
97. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992;11:3053-3058.
98. Bukrinsky MI, Haggerty S, Dempsey MP et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993;365:666-669.
99. Blomer U, Naldini L, Kafri T et al. Highly efficient and sustained gene transfer in adult neurons with a lentiviros vector. J Virol 1997;71:6641-6649.
100. Miller RH, Sarver N. HIV accessory proteins as therapeutic targets. Nat Med 1997;3:389-394.
101. Enders JF, Bell JA, Dingle JH et al. "Adenoviruses" group name proposed for new respiratory tract viruses. Science 1956;124:119-120.
102. Zabner J, Couture LA, Gregory RJ et al. Adenovirus-mediated gene transfer transiently corrects the chlorine transport defect in nasal epithelia of patients with CF. Cell 1993;75:207-216.
103. Caruso M, Pham-Nguyen K, Kwong Y-L et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996;93:11302-11306.
104. Hermens WT, Giger RJ, Holtmaat AJ et al. Transient gene transfer to neurons and glia: analysis of adenoviral vector performance in the CNS and PNS. J Neurosci Methods 1997;71:85-98.
105. van Esseveldt KE, Liu R, Hermens WT et al. Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus. J Neurosci Methods 1997;71:113-123.
106. Liu G, Excoffon KJ, Benoit P et al. Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Hum Gene Ther 1997;8:205-214.
107. Pierzchalski P, Reiss K, Cheng W et al. p53 induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res 1997;234:57-65.
108. Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
109. Yei S, Mittereder N, Tang K et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1994;1:192-200.
110. Engelhardt JF, Ye X, Doranz B et al. Ablation of E2A in recombinant adenovirus improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-6200.
111. Yang Y, Nunes FA, Berencsi K et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-369.
112. Yeh P, Dedieu JF, Orsini C et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996;70:559-565.
113. Dedieu JF, Vigne E, Torrent C et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997;71:4626-4637.
114. Vilquin JT, Guerette B, Kinoshita I et al. FK506 immuno-suppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995;6:1391-1401.
115. Kass-Eisler A, Leinwand L, Gall J et al. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996;3:154-162.
116. Gall J, Kass-Eisler A, Leinwand L et al. Adenovirus type 5 and type 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996;70:2116-2123.
117. Russel DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994;91:8915-8919.
118. Linden RM, Ward P, Giraud C et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1996;93:11288-11294.
119. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997;71:3299-3306.
120. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996;7:2101-2112.
121. Buller RM, Janik JE, Sebring ED et al. Herpes simplex virus type 1 and 2 completely help adenovirus-associated virus replication. J Virol 1981;40:241-247.
122. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA 1966;55:1467-1474.
123. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991;65:2476-2483.
124. Zhou SZ, Cooper S, Kang LY et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 1994;179:1867-1875.
125. Kaplitt MG, Leone P, Samulski RJ et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154.
126. Ali RR, Reichel MB, Thrasher AJ et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996;5:591-594.
127. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996;70:8098-8108.
128. Wagner JA, Gardner P. Toward cystic fibrosis gene therapy. Annu Rev Med 1997;48;203-216.
129. Behr JP. Gene transfer with synthetic cationic amphiles: prospects for gene therapy. Bioconjug Chem 1994;5:382-389.
130. Behr JP, Demeneix B, Loeffler JP et al. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 1989;86:6982-6986.
131. Felgner PL, Gadek TR, Holm M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7417.
132. Gotten M, Wagner E. Non-viral approaches to gene therapy. Curr Opin Biotechnol 1993;4:705-710.
133. Michael SI, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther 1994;1:223-232.
134. Perales JC, Ferkol T, Molas M et al. An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur J Biochem 1994;226:255-266.
135. Smythe E, Warren G. The mechanism of receptor-mediated endocytosis. Eur J Biochem 1991;202:689-699.
136. Caplen NJ, Alton EW, Middleton PG et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39-46.